Market capitalization | $440.44m |
Enterprise Value | $235.89m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.92 |
P/S ratio (TTM) P/S ratio | 9.19 |
P/B ratio (TTM) P/B ratio | 550.68 |
Revenue growth (TTM) Revenue growth | 38.82% |
Revenue (TTM) Revenue | $47.94m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
6 Analysts have issued a Cartesian Therapeutics forecast:
6 Analysts have issued a Cartesian Therapeutics forecast:
Sep '24 |
+/-
%
|
||
Revenue | 48 48 |
39%
39%
|
|
Gross Profit | 47 47 |
45%
45%
|
|
EBITDA | -52 -52 |
8%
8%
|
EBIT (Operating Income) EBIT | -53 -53 |
10%
10%
|
Net Profit | -287 -287 |
693%
693%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Carsten Brunn |
Employees | 38 |
Founded | 2007 |
Website | www.cartesiantherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.